Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Cabaletta Bio, Inc. (CABA) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/31/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cabaletta Bio, Inc. Corporate Presentation, furnished herewith",
"- IND application cleared within 6 months of in-licensing CABA-201 binder - CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be evaluated and the patient dosing intervals"
03/16/2023 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update",
"Cabaletta Bio, Inc. Corporate Presentation, furnished herewith"
03/06/2023 8-K Investor presentation
Docs: "Cabaletta Bio, Inc. Corporate Presentation",
"Cabaletta Bio, Inc. Corporate Presentation"
01/09/2023 8-K Investor presentation
Docs: "Cabaletta Bio, Inc. Corporate Presentation"
12/08/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/11/2022 8-K Investor presentation
Docs: "Cabaletta Bio, Inc. Corporate Presentation, furnished herewith",
"Cabaletta Bio and IASO Biotherapeutics Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder PHILADELPHIA, Pennsylvania and SAN JOSE, California, NANJING and SHANGHAI, China — October 11, 2022 — IASO Biotherapeutics , a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines and Cabaletta Bio, Inc. , a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the companies entered into an agreement pursuant to which Cabaletta obtained from IASO Bio an exclusive, worldwide license to develop, manufacture and commercialize a clinically validated fully-human CD19 binder for use in product...",
"Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases"
09/12/2022 8-K Investor presentation
Docs: "Cabaletta Bio, Inc. Corporate Presentation, furnished herewith",
"Cabaletta Bio Presents New Interim Data from the DesCAARTes ™ Phase 1 Trial at the 31st EADV Congress"
08/11/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
03/17/2022 8-K Investor presentation, Quarterly results
Docs: "Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update",
"Cabaletta Bio, Inc. Corporate Presentation, furnished herewith"
03/03/2022 8-K Quarterly results
01/10/2022 8-K Investor presentation
Docs: "Cabaletta Bio, Inc. Corporate Presentation, furnished herewith"
12/14/2021 8-K Quarterly results
11/01/2021 8-K Investor presentation, Quarterly results
Docs: "Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update",
"Cabaletta Bio, Inc. Corporate Presentation, dated November 2021, furnished herewith",
"Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes ™ Trial in Patients with mPV"
08/18/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
04/06/2021 8-K Quarterly results
06/03/2020 8-K Investor presentation
Docs: "Cabaletta Bio, Inc. Corporate Presentation",
"Cabaletta Bio, Inc. Corporate Presentation"
02/20/2020 8-K Investor presentation
Docs: "Cabaletta Bio, Inc. Corporate Presentation",
"Cabaletta Bio, Inc. Corporate Presentation"
01/10/2020 8-K Investor presentation
Docs: "Cabaletta Bio, Inc. Corporate Presentation",
"Cabaletta Bio, Inc. Corporate Presentation"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy